IMCT-17STATISTICALLY SIGNIFICANT ASSOCIATION OF GLIOBLASTOMA IMMUNOTHERAPY PHASE II CLINICAL STUDY (ICT-107) TREATMENT AND SURVIVAL TO IMMUNE RESPONSE USING A NOVEL COMPREHENSIVE ELISPOT ANALYSIS
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.